CSIMarket Company Name, Ticker, Suppliers, else..
 
Zomedica Corp   (NYSE: ZOM)
Other Ticker:  
 
 
Price: $0.1239 $0.00 -0.402%
Day's High: $0.1274 Week Perf: -4.47 %
Day's Low: $ 0.12 30 Day Perf: -1.12 %
Volume (M): 4,246 52 Wk High: $ 0.20
Volume (M$): $ 526 52 Wk Avg: $0.14
Open: $0.12 52 Wk Low: $0.12



 Market Capitalization (Millions $) 121
 Shares Outstanding (Millions) 980
 Employees 16
 Revenues (TTM) (Millions $) 26
 Net Income (TTM) (Millions $) -62
 Cash Flow (TTM) (Millions $) -12
 Capital Exp. (TTM) (Millions $) 7

Zomedica Corp
Zomedica Corp is a veterinary pharmaceutical company that develops and commercializes medical devices and drugs for pets. The company focuses on developing innovative solutions to enhance the overall healthcare of animals. Their products include diagnostics, therapeutics, and devices that aim to improve the diagnostic accuracy and treatment options for veterinarians. Zomedica Corp is committed to advancing animal health through their research and development efforts, as well as their partnerships with veterinarians and animal health companies.


   Company Address: 100 Phoenix Drive Ann Arbor 48108 MI
   Company Phone Number: 369-2555   Stock Exchange / Ticker: NYSE ZOM


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ELAN      % 
VTRS      % 
ZTS      % 
IDXX      % 
NEOG      % 
OSW      % 
• View Complete Report
   



Zomedica Corp

Zomedica Corp: Achieving Impressive Revenue Growth in Q1 2024

The stock market can sometimes be a rollercoaster ride, with ups and downs that can make even the most seasoned investor a little queasy. But amidst the fluctuations, there are always shining stars that capture the attention and admiration of market participants. And one such star is Zomedica Corp, which has showcased impressive growth and potential in the recent quarter report.
In the Mar 31 2024 report, Zomedica Corp displayed a remarkable 11.583% increase in revenue compared to the similar quarter of the previous year, reaching an impressive $6.12 million. This surge in revenue is a testament to the company's unwavering commitment to excellence and its ability to stand out in the competitive market of Major Pharmaceutical Preparations.
Zomedica Corp

Zomedica Corp Sees Widening Losses in Financial Fourth Quarter of 2023

Zomedica Corp, a major pharmaceutical preparations company, has experienced some fluctuations in its stock price over the last few trading days. Although the stock showed a slight improvement of 0.07% in the past five trading days, it has seen a significant decline of 34.88% over the past 90 days. Additionally, the stock currently trades at a level that is only 16.7% above its 52-week low.
In terms of financial performance, Zomedica Corp reported a loss per share of $-0.02 in the fourth quarter of 2023, a decrease from the previous quarter's loss of $-0.05 per share. However, the company's revenue showed a promising surge of 36.852%, reaching $8.43 million compared to $5.36 million in the same reporting period a year ago.
Zomedica Corp

Zomedica Corp Achieves Record-breaking $5.362 Million Top-line in Q3 - Paving the Way for Success in 2023



Zomedica Corp, a major player in the field of pharmaceutical preparations, has recently reported its third-quarter earnings for 2023. While the company managed to achieve break-even on a per-share basis and witnessed a slight increase in revenue, several concerning factors indicate a potential decline in its overall business performance. This article aims to delve into the various reasons supporting a bearish outlook on Zomedica Corp.
Underwhelming Financial Performance:
ZOM's break-even earnings per share for Q3 2023, while an improvement compared to the previous year, remain lackluster. It is concerning that the company hasn't demonstrated significant growth in earnings despite operating in a market that witnessed a revenue gain of 12.27% in the same reporting season. This suggests that Zomedica Corp is struggling to capitalize on the growth potential in the Major Pharmaceutical Preparations sector.
Zomedica Corp

Zomedica Corp Smashes Expectations with Remarkable 18.888% Revenue Growth in Q2 2023

As an analyst covering the financial markets, I have been closely monitoring Zomedica Corp's recent financial results and its stock performance. The company's fiscal results for the time-frame ending June 30, 2023, have certainly raised eyebrows and sparked discussion within the investment community.
Zomedica Corp reported a loss of $-0.01 per share for the period, which is consistent with the previous year and the prior reporting period. While this may not have been unexpected, it is worth noting that Zomedica Corp managed to achieve a notable revenue increase of 18.888% compared to the same period a year ago. This is particularly impressive when considering the major pharmaceutical preparations industry's average contraction in revenue of -9.44%.
Zomedica Corp

Zomedica Corp's Surge in Revenue Fails to Make Company Profitable, Reporting Net Loss of $6.4 Million in Latest Financial Results

Zomedica Corp, a veterinary diagnostic and pharmaceutical company, has reported its financial results for its fiscal timeframe ending March 31, 2023. The company experienced a surge in revenue of 46.148%, reaching $5.48 million from the same period a year earlier. However, the company's net loss increased to $-6.385 million, up from $-3.937 million.
Despite the growth in revenue, Zomedica Corp experienced a loss per share of $-0.01 from the same time-frame a year prior when it reported zero earnings per share. The company's net loss also increased by over $2 million.






Zomedica's Segments
Capital    36.98 % of total Revenue
Consumables    77.71 % of total Revenue
Other    0.78 % of total Revenue
Diagnostics    8.37 % of total Revenue
Diagnostics Capital    2.77 % of total Revenue
Diagnostics Consumables    5.59 % of total Revenue
Therapeutic Devices    107.1 % of total Revenue
Therapeutic Devices Capital    34.21 % of total Revenue
Therapeutic Devices Consumables    72.11 % of total Revenue
Therapeutic Devices Other    0.78 % of total Revenue





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com